Hyaluronic Acid as A Biomarker for Liver Fibrosis in Chronic Hepatitis “C” Patients | ||||
| Minia Journal of Medical Research | ||||
| Article 2, Volume 30, Issue 4, October 2019, Page 7-9 PDF (658.49 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mjmr.2022.221592 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Madiha M. A. Makhlouf; Ehab M. A. Raheem; Lamiaa H. Aly; Mahmoud O. Abdel-Wahab | ||||
| Department of Tropical Medicine, El-Minia Faculty of Medicine | ||||
| Abstract | ||||
| Introduction: Because of that and its short half-life in blood (2–5 min), serum HA levels can reflect liver fibrosis stage and were incorporated into a long list of serum noninvasive liver fibrosis markers such as procollagen III N-terminal propeptide (PIIINP), laminin and transforming growth factor beta (TGF-b) (Afdhal NH, Nunes D., 2004). It was found that serum levels of hyaluronic acid are elevated in chronic liver diseases in which the serum levels of ECM would be changed. These include alcoholic and non-alcoholic steatohepatitis, hepatitis B, C and others (Rostami S, et al., 2013). Patient And Methods: This study was designed to evaluate the effect of antiviral therapy on the serum hyaluronic acid as abiomarker of fibrosis ;in patients with chronic hepatitis C. Results: We found that serum hyaluronic acid level showed asignificant decrease after treatment. Recommendations: Hyaluronic acid can be used to determine the stage of fibrosis when liver biopsy is contraindicated. | ||||
| Keywords | ||||
| Hyaluronic Acid; Liver Fibrosis; Chronic Hepatitis “C” | ||||
|
Supplementary Files
|
||||
|
Statistics Article View: 106 PDF Download: 134 |
||||
